Malignant phenotype of renal cell carcinoma cells is switched by Ukrain administration in vitro

Anti-Cancer Drugs

Volumn 22, Issue 8, 2011, Pages 749-762

  Gagliano, Nicoletta ^a   Pettinari, Letizia ^a   Aureli, Massimo ^b   Martinelli, Carla ^a   Colombo, Elena ^c   Costa, Francesco ^a   Carminati, Roberta ^a   Volpari, Tatiana ^a   Colombo, Graziano ^c   Milzani, Aldo ^c   Dalle Donne, Isabella ^c   Gioia, Magda ^a  

^a Extracellular Matrix Laboratory   (Italy)

^b Department of Medical Chemistry Biochemistry and Biotechnology ^*  (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

cytoskeleton; epithelial to mesenchymal transition; matrix metalloproteinases; renal cell carcinoma; secreted protein acidic and rich in cysteine; tumor invasion

Indexed keywords

ACTIN; BETA CATENIN; GELATINASE A; GELATINASE B; OSTEONECTIN; TUBULIN; UKRAIN; VIMENTIN;

ARTICLE; CANCER GROWTH; CANCER INVASION; CARCINOMA CELL; CELL CYCLE; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; KIDNEY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SUPERNATANT; TUMOR MICROENVIRONMENT; WESTERN BLOTTING; ZYMOGRAPHY;

ANTINEOPLASTIC AGENTS; BERBERINE ALKALOIDS; CARCINOMA, RENAL CELL; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; NEOPLASM INVASIVENESS; PHENANTHRIDINES; PHENOTYPE; TUMOR MICROENVIRONMENT;

EID: 80051521857     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328346c7f7     Document Type: Article

References (60)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353:2477-2490. (Pubitemid 41770167)
2. Zisman A, Pantuck AJ, Wieder J Chao DH, Dorey F, Said JW, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20:4559-4566. (Pubitemid 35402959)
3. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2:442-454.
4. Kang Y, Massagué J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004; 118:277-279. (Pubitemid 39061108)
5. Hendrix MJC, Luo J, Seftor EA, Sharma N, Heidger PM Jr, Cohen MB, et al. Epithelial-mesenchymal molecular interactions in prostatic tumor cell plasticity. In: Ablin RJ, Mason MD, editors. Metastasis of prostate cancer. Dordrecht, The Netherlands: Springer Academic Publishers; 2007. pp. 127-141.
6. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172:973-981.
7. Kretmair H. Hypericum perforatum, St John's wort. Pharmazie 1950; 5:85-88.
8. Susak YM, Zemskov VS,Yaremchuk OY, Kravchenco OB, Yatsyk IM, Korsh OB. Comparison of chemotherapy and X-ray therapy with Ukrain monotherapy for colorectal cancer. Drugs Exp Clin Res 1996; 22:115-122. (Pubitemid 26336258)
9. Uglianitsa KN, Nechiporenko NA, Nefyodov LI, Brzosko WJ. Ukrain therapy of stage T1N0M0 bladder cancer patients. Drugs Exp Clin Res 1998; 24:227-230. (Pubitemid 29126752)
10. Uglianitsa KN, Nefyodov LI, Brzosko W. Evaluation of the efficacy of Ukrain in the treatment of breast cancer: clinical and laboratory studies. Drugs Exp Clin Res 1998; 24:231-239. (Pubitemid 29126753)
11. Zemskov V, Prokopchuk O, Susak Y, Zemskov S, Tkachenko O, Hodysh Y, et al. Efficacy of Ukrain in the treatment of pancreatic cancer. Langenbecks Arch 2002; 387:84-89. (Pubitemid 36061888)
12. Ernst E, Schmidt K. Ukrain-a new cancer cure? A systematic review of randomised clinical trials. BMC Cancer 2005; 5:69.
13. Gansauge F, Ramadani M, Schwarz M, Beger HG, Lotspeich E, Poch B. The clinical efficacy of adjuvant systemic chemotherapy with gemcitabine and NSC-631570 in advanced pancreatic cancer. Hepatogastroenterol 2007; 54:917-920. (Pubitemid 46903753)
14. Funel N, Costa F, Pettinari L, Taddeo A, Sala A, Chiriva-Internati M, et al. Ukrain Affects Pancreas Cancer Cell Phenotype in vitro by Targeting MMP-9 and Intra-/Extracellular SPARC Expression. Pancreatology 2010; 10:545-552.
15. Liepins A, Nowicky JW. Activation of spleen cell lytic activity by the alkaloid thiophosphoric acid derivative: Ukrain. Int J Immunopharmac 1992; 14:1437-1442.
16. Liepins A, Nowicky JW, Bustamante JO, Lam E. Induction of bimodal programmed cell death in malignant cells by the derivative Ukrain NSC-631570. Drugs Exp Clin Res 1996; 22:73-79. (Pubitemid 26336253)
17. Roublevskaia IN, Polevoda BV, Ludlow JW, Haake AR. Induced G2/M arrest and apoptosis in human epidermoid carcinoma cell lines by semisynthetic drug Ukrain. Anticancer Res 2000; 20:3163-3167.
18. Habermehel D, Kammerer B, Handrick R, Eldh T, Gruber C, Cordes G, et al. Proapoptotic activity of Ukrain is based on Chelidonium majus L. alkaloids and mediated via a mitochondrial death pathway. BMC Cancer 2006; 6:14.
19. Gagliano N, Moscheni C, Torri C, Donetti E, Magnani I, Costa F, et al. Ukrain modulates glial fibrillary acidic protein, but not connexin 43 expression, and induces apoptosis in human cultured glioblastoma cells. Anticancer Drugs 2007; 18:669-676. (Pubitemid 47343659)
20. Erba E, Bassano L, Di Liberti G, Muradore I, Chiorino G, Ubezio P, et al. Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. Br J Cancer 2002; 86:1510-1517. (Pubitemid 34548077)
21. Trevor KT, McGuire JG, Leonova E. Association of vimentin intermediate filaments with the centrosome. J Cell Science 1995; 108:343-356.
22. Nowicky JW, Hiesmayr W, Nowicky W, Liepins A. Influence of Ukrain on DNA, RNA and protein synthesis in malignant cells. Drugs Exp Clin Res 1996; 22:81-91. (Pubitemid 26336254)
23. Panzer A, Joubert AM, Bianchi PC, Hamel E, Seegers JC. The effects of chelidonine on tubulin polymerisation, cell cycle progression and selected signal transmission pathways. Eur J Cell Biol 2001; 80:111-118. (Pubitemid 32098117)
24. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 59:1465-1475. (Pubitemid 32947976)
25. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303:1483-1487. (Pubitemid 38314410)
26. Kim G, Rajasekaran SA, Thomas G, Rosen EA, Landaw EM, Shintaku P, et al. Renal clear-cell carcinoma: an ultrastructural study on the junctional complexes. Histol Histopathol 2005; 20:35-44. (Pubitemid 40028981)
27. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, et al. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J 2002; 21:1948-1956. (Pubitemid 34437192)
28. Van Es JH, Barker N, Clevers H. You WNTsome, you lose some: oncogenes in the WNT signaling pathway. Curr Opin Genet Dev 2003; 13:28-33. (Pubitemid 36143924)
29. Pawlak G, Helfman DM. Cytoskeletal changes in cell transformation and tumorigenesis. Curr Opin Genet Dev 2001; 11:41-47. (Pubitemid 32119276)
30. Savagner P. Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays 2001; 23:912-923. (Pubitemid 32972691)
31. Ayollo DV, Zhitnyak IY, Vasiliev JM, Gloushankova NA. Rearrangements of the actin cytoskeleton and E-cadherin-based adherens junctions caused by neoplasic transformation change cell-cell interactions. PLoS One 2009; 4:e8027.
32. Martel C, Harper F, Cereghini S, Noë V, Mareel M, Cré misi C. Inactivation of retinoblastoma family proteins by sv4o t antigen results in creation of a hepatocyte growth factor/scatter factor autocrine loop associated with an epithelial-fibroblastoid conversion and invasiveness. Cell Growth Differ 1997; 8:165-178. (Pubitemid 27068894)
33. Mendez MG, Kojima S-I, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. FASEB J 2010; 24:1838-1851.
34. Hendrix MJC, Seftor EA, Chu YW, Trevor KT, Seftor RE. Role of intermediate filaments in migration, invasion and metastasis. Cancer Metast Rev 1996; 15:507-525. (Pubitemid 27067169)
35. Iyer PV, Leong AS. Poorly differentiated squamous cell carcinomas of the skin can express vimentin. J Cutan Pathol 1992; 19:34-39.
36. Rajasekaran SA, Gopal J, Espineda C, Ryazantsev S, Schneeberger EE, Rajasekaran AK. HPAF-II, a cell culture model to study pancreatic epithelial cell structure and function. Pancreas 2004; 29:e77-e83.
37. Christiansen JJ, Rajasekaran AK. Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 2006; 66:8319-8326. (Pubitemid 44449137)
38. Kessenbrock K, Plaks V,Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141:52-67.
39. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000; 6:149-156. (Pubitemid 30171365)
40. Liotta LA, Stetler-Stevenson WG. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 1991; 51:5054s-5059s.
41. Collier IE, Wilhelm SM, Eisen AZ, Marmer BL, Grant GA, Seltzer JL, et al. H-ras oncogene transformed human bronchial epithelial cells (TBE-1) secrete a single metalloproteinase capable of degrading basement membrane collagen. J Biol Chem 1988; 263:6579-6587.
42. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 2001; 7:3113-3119. (Pubitemid 32963832)
43. Takahashi M, Oka N, Naroda T, Nishitani MA, Kanda K, Kanayama HO, et al. Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma. Int J Urol 2002; 9:531-538. (Pubitemid 35370724)
44. Kawata N, Nagane Y, Igarashi T, Hirakata H, Ichinose T, Hachiya T, et al. Strong significant correlation between MMP-9 and systemic symptoms in patients with localized renal cell carcinoma. Urology 2006; 68: 523-527. (Pubitemid 44436510)
45. Kawata N, Nagane Y, Hirakata H, Ichinose T, Okada Y, Yamaguchi K, et al. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma. Urology 2007; 69:1049-1053. (Pubitemid 46891585)
46. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 2001; 107:1049-1054. (Pubitemid 32422898)
47. Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix communication. Matrix Biol 2000; 19:569-580.
48. Wewer UM, Albrechtsen R, Fisher LW, Young MF, Termine JD. Osteonectin/SPARC/BM-40 in human decidua and carcinoma, tissues characterized by de novo formation of basement membrane. Am J Pathol 1988; 132:345-355.
49. Porte H, Chastre E, Prevot S, Nordlinger B, Empereur S, Basset P, et al. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 1995; 64:70-75.
50. Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 1997; 108:210-214. (Pubitemid 27061034)
51. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 1999; 30:339-344. (Pubitemid 29125155)
52. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 2000; 6:1140-1149. (Pubitemid 30159378)
53. Yamanaka M, Kanda K, Li NC, Fukumori T, Oka N, Kanayama HO, et al. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 2001; 166:2495-2499. (Pubitemid 33065342)
54. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, et al. SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 2001; 159:609-622. (Pubitemid 32751091)
55. Motamed K, Sage EH. Regulation of vascular morphogenesis by the matricellular protein SPARC. Kidney Int 1997; 51:1383-1387. (Pubitemid 27239887)
56. Rempel SA, Golembieski WA, Fisher JL, Maile M, Nakeff A. SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. J Neurooncol 2001; 53:149-160. (Pubitemid 33034688)
57. Said N, Motamed K. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 2005; 167:1739-1752. (Pubitemid 41713324)
58. Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, et al. Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia 2009; 11: 126-135.
59. Funk SE, Sage EH. Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. J Cell Physiol 1993; 154:53-63. (Pubitemid 23023995)
60. Gooden MD, Vernon RB, Bassuk JA, Sage EH. Cell cycle-dependent nuclear location of the matricellular protein SPARC: association with the nuclear matrix. J Cell Biochem 1999; 74:152-167. (Pubitemid 29307706)